NEWAMSTERDAM PHARMA CO NV

Insider buying spurs hope for NewAmsterdam Pharma: Kastelein’s recent share surge hints at a breakthrough, but R&D costs and a negative P/E warn of risk.

Insider buying at a 30% discount signals NewAmsterdam Pharma may be undervalued; CFO’s mixed trades reveal confidence and liquidity needs.

Newamsterdam Pharma insider sale: LANGE LOUIS G sold 28,186 shares at $29.41 amid a 2.85% rally, highlighting strategic hedging rather than a red flag for investors.

CEO Davidson’s recent Newamsterdam Pharma trades show confidence in the clinical pipeline, boosting his stake while navigating tax‑savvy moves.

Newamsterdam Pharma insider activity: CAO Louise Kooij’s recent $10‑12 buys amid heavy option sales reveal cautious optimism and hedging tactics ahead of key clinical milestones.

Insider buying spree: Kooij Louise Frederika’s $10‑share purchases signal confidence in Newamsterdam’s upcoming clinical milestones, hinting at a potential upside.

Newamsterdam Pharma CFO’s large Rule‑10b5‑1 buy signals confidence in undervalued stock amid negative earnings, highlighting insider strategy for investors.

Newamsterdam Pharma insider activity: CFO’s sell‑to‑cover sale vs. new RSU and option grants shows confidence, low dilution and potential upside tied to clinical milestones.

Newamsterdam Pharma insider trades show executive confidence, aligning RSU and option moves with long‑term growth and a rising small‑molecule pipeline.